LND 796

Drug Profile

LND 796

Alternative Names: Cordil; LNF 209

Latest Information Update: 10 Aug 1998

Price : $50

At a glance

  • Originator Nativelle
  • Developer Nativelle; Procter & Gamble
  • Class Antiarrhythmics; Cardiac glycosides; Cardiotonics; Steroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 10 Aug 1998 No-Development-Reported for Heart failure in USA (Unknown route)
  • 10 Aug 1998 No-Development-Reported for Heart failure in France (Unknown route)
  • 15 May 1996 A study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top